1. Home
  2. CBC vs ERAS Comparison

CBC vs ERAS Comparison

Compare CBC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Bancompany Inc.

CBC

Central Bancompany Inc.

N/A

Current Price

$32.26

Market Cap

7.7B

Sector

N/A

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

BUY

Current Price

$15.53

Market Cap

6.3B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CBC
ERAS
Founded
1902
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
6.3B
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CBC
ERAS
Price
$32.26
$15.53
Analyst Decision
Buy
Buy
Analyst Count
5
9
Target Price
★ $34.60
$24.11
AVG Volume (30 Days)
1.2M
★ 4.4M
Earning Date
10-27-2026
11-11-2026
Dividend Yield
★ 1.51%
N/A
EPS Growth
25.90
★ 36.23
EPS
★ 0.94
N/A
Revenue
N/A
N/A
Revenue This Year
$8.45
N/A
Revenue Next Year
$5.25
N/A
P/E Ratio
$33.89
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.50
$2.11
52 Week High
$33.82
$24.28

Technical Indicators

Market Signals
Indicator
CBC
ERAS
Relative Strength Index (RSI) 54.49 49.51
Support Level $31.93 $13.48
Resistance Level $32.36 $16.14
Average True Range (ATR) 0.65 0.95
MACD 0.06 0.11
Stochastic Oscillator 93.21 80.58

Price Performance

Historical Comparison
CBC
ERAS

About CBC Central Bancompany Inc.

Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: